Nurix Therapeutics: Why This Company Could Double In Value? [Seeking Alpha]
Nurix Therapeutics, Inc. - Common stock (NRIX)
Company Research
Source: Seeking Alpha
Phase 1 data showed an 83% response rate at 600mg and 22.1 months of progression-free survival, enabling direct advancement to phase 3 trials. NRIX holds $680M in cash, supporting R&D through 2027-2028 and minimizing dilution risk for shareholders. With a current EV of $1.22B and risk-adjusted sales potential of $3B, NRIX offers a compelling risk-reward profile, though competition and regulatory risks remain. Getty Images Nurix Therapeutics ( NRIX ) presents a turning point in treating Chronic Lymphocytic Leukemia (CLL) and immune diseases. The CLL treatment is a large market and has long been dominated by BTK inhibitors such as Ibrutinib and Pirtobrutinib. The problem with these This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in NRIX over the next
Show less
Read more
Impact Snapshot
Event Time:
NRIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRIX alerts
High impacting Nurix Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
NRIX
News
- Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases [Yahoo! Finance]Yahoo! Finance
- Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune DiseasesGlobeNewswire
- Nurix Therapeutics (NASDAQ:NRIX) was given a new $36.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.MarketBeat
- Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics' Degrader Platform (NRIX)? [Yahoo! Finance]Yahoo! Finance
NRIX
Earnings
- 10/9/25 - Miss
NRIX
Sec Filings
- 1/12/26 - Form 8-K
- 12/18/25 - Form 4
- 12/18/25 - Form 144
- NRIX's page on the SEC website